Genetic disorders contribute to 7.6 percent of disability-adjusted life years worldwide. In the United States 20.8 percent of adult deaths link to genetic environmental or behavioral risk factors for heart disease diabetes and cancer. Data on testing volumes diagnostic yields and market scale show current patterns in detection and care.
Key Takeaways
- In the U.S., 20.8% of adult deaths in 2020 were attributable to genetic, environmental, or behavioral risk factors for a family history of heart disease, diabetes, and cancer (risk factor-related mortality share)
- Between 2018 and 2022, genetic disorders accounted for 7.6% of all disability-adjusted life years (DALYs) in the Global Burden of Disease Study 2019 as the broad category “neurological disorders” and “genetic disorders”—(genetic disorders share reported in GBD comparative risk context)
- $24.7 billion global genetic testing market projected for 2032 (industry estimate)
- $6.4 billion global prenatal genetic testing market size in 2023 (industry estimate)
- $20.4 billion global pharmacogenomics testing market projected for 2032 (industry estimate)
- ~50% of Americans have participated in direct-to-consumer genetic testing at least once (survey-based)
- In a survey of clinical genetic testing providers, 87% reported that they use NGS for at least some tests
- In a 2021 survey, 69% of patients were interested in genetic testing if recommended by a clinician (survey-based)
- In 2023, the FDA approved 19% of drugs in oncology as companion-diagnostic linked (industry-regulatory linkage trend quantified)
- In the ClinVar database, over 1.5 million variant submissions are included (curated count)
- UniProt contains over 250 million protein sequence entries as of 2024 (biological data scale impacting genetic research)
- In a prospective study, diagnostic yield of exome sequencing for rare disease was 25% (reported yield)
- In a large cohort study, clinical exome sequencing achieved a diagnostic rate of 33% for patients with suspected genetic disorders (reported)
- Whole-exome sequencing diagnostic yield ranged from 20% to 30% across cohorts in a systematic review (range reported)
Genetic testing and targeted therapies are rapidly expanding, driven by growing evidence of genetic burden and clinical value.
Related reading
01 · Category
Prevalence And Burden2 stats
01
In the U.S., 20.8% of adult deaths in 2020 were attributable to genetic, environmental, or behavioral risk factors for a family history of heart disease, diabetes, and cancer (risk factor-related mortality share)
02
Between 2018 and 2022, genetic disorders accounted for 7.6% of all disability-adjusted life years (DALYs) in the Global Burden of Disease Study 2019 as the broad category “neurological disorders” and “genetic disorders”—(genetic disorders share reported in GBD comparative risk context)
Interpretation
Prevalence And Burden Interpretation
Genetic disorders create a substantial and measurable prevalence and burden, contributing to 20.8% of adult deaths in the U.S. in 2020 through genetic, environmental, or behavioral risks tied to family history and accounting for 7.6% of global disability-adjusted life years from 2018 to 2022.
02 · Category
Market Size15 stats
01
$24.7 billion global genetic testing market projected for 2032 (industry estimate)
02
$6.4 billion global prenatal genetic testing market size in 2023 (industry estimate)
03
$20.4 billion global pharmacogenomics testing market projected for 2032 (industry estimate)
04
The global companion diagnostics market is projected to reach $15.0 billion by 2030 (industry estimate)
05
The global precision medicine market size was $67.6 billion in 2023 and is projected to reach $184.0 billion by 2028 (industry estimate)
06
The global genetic testing market is projected to reach $90.7 billion by 2030 (industry estimate)
07
$7.1 billion global NGS instruments market size in 2023 (industry estimate)
08
$1.7 billion global CRISPR diagnostics market projected for 2027 (industry estimate)
09
$7.2 billion global rare disease therapeutics market size in 2023 (industry estimate)
10
$11.6 billion global rare disease diagnostics market projected by 2030 (industry estimate)
11
$3.8 billion global lysosomal storage disorder therapeutics market in 2023 (industry estimate)
12
$2.1 billion global SMA therapeutics market size in 2023 (industry estimate)
13
$4.5 billion global hemophilia therapeutics market size in 2023 (industry estimate)
14
$8.0 billion global inherited retinal disease therapeutics market projected for 2032 (industry estimate)
15
$6.2 billion global personalized medicine market size in 2023 (industry estimate)
Interpretation
Market Size Interpretation
The market size for genetic disorder related testing and related precision medicine is expanding rapidly, with the global genetic testing market projected to reach $90.7 billion by 2030 alongside precision medicine growing from $67.6 billion in 2023 to $184.0 billion by 2028.
03 · Category
User Adoption6 stats
01
~50% of Americans have participated in direct-to-consumer genetic testing at least once (survey-based)
02
In a survey of clinical genetic testing providers, 87% reported that they use NGS for at least some tests
03
In a 2021 survey, 69% of patients were interested in genetic testing if recommended by a clinician (survey-based)
04
An estimated 30% of hereditary cancer patients receive genetic testing (observational estimate in a clinical study)
05
~1-2% of all births require confirmatory diagnostic genetic testing after abnormal newborn screening results (newborn screening follow-up proportion)
06
10% of adults reported having had genetic testing for health reasons in 2019 (survey estimate)
Interpretation
User Adoption Interpretation
User adoption is steadily expanding, with about 50% of Americans having used direct-to-consumer genetic testing at least once and 69% of patients saying they would pursue genetic testing when recommended by a clinician, even as testing coverage remains incomplete for groups like hereditary cancer patients where only about 30% receive it.
More related reading
04 · Category
Industry Trends8 stats
01
In 2023, the FDA approved 19% of drugs in oncology as companion-diagnostic linked (industry-regulatory linkage trend quantified)
02
In the ClinVar database, over 1.5 million variant submissions are included (curated count)
03
UniProt contains over 250 million protein sequence entries as of 2024 (biological data scale impacting genetic research)
04
The number of pathogenic variants in ClinVar exceeds 150,000 (curated count)
05
The gnomAD database contains genetic data from approximately 200,000+ exomes and 100,000+ genomes (population scale)
06
The number of samples in UK Biobank exceeded 500,000 participants by 2018 and continues expanding (cohort size)
07
The NCBI Sequence Read Archive (SRA) has over 2 quadrillion bases (data volume scale relevant to genetic disorders research)
08
In 2023, the FDA received 9,000+ medical device and in vitro diagnostic submissions overall; genetic testing is a growing portion (regulatory submission trend)
Interpretation
Industry Trends Interpretation
Industry momentum in genetic disorders is accelerating as the FDA approved 19% of oncology drugs in 2023 as companion-diagnostic linked therapies alongside rapid growth in biomedical data infrastructure, including over 1.5 million ClinVar variant submissions and gnomAD scale reaching about 200,000+ exomes and 100,000+ genomes.
05 · Category
Performance Metrics10 stats
01
In a prospective study, diagnostic yield of exome sequencing for rare disease was 25% (reported yield)
02
In a large cohort study, clinical exome sequencing achieved a diagnostic rate of 33% for patients with suspected genetic disorders (reported)
03
Whole-exome sequencing diagnostic yield ranged from 20% to 30% across cohorts in a systematic review (range reported)
04
A systematic review reported that chromosomal microarray analysis detects pathogenic variants in 10%–20% of individuals with unexplained developmental delay/intellectual disability (range reported)
05
In clinical use, amniocentesis has a procedure-related miscarriage risk estimated at about 0.1% (risk quantification)
06
CVS miscarriage risk is about 0.2% above background risk (quantified clinical risk)
07
In a study of newborn screening using tandem mass spectrometry, false positive rate was reported at 0.2% (reported rate)
08
In a validation study, analytic sensitivity for a common single-gene NGS assay was >99% for detecting variants down to a specified allele fraction (reported analytic performance)
09
In a randomized clinical trial, pharmacogenomics-guided therapy reduced time to effective dosing by 2 weeks (quantified outcome)
10
In a meta-analysis, gene panel testing had an overall diagnostic yield of ~30% in suspected inherited disorders (quantified)
Interpretation
Performance Metrics Interpretation
Across performance metrics for genetic testing, diagnostic yields cluster in a fairly tight band with exome sequencing landing at 25% to 33% and whole exome review ranges of 20% to 30%, while cytogenetic and microarray approaches tend to be lower at about 10% to 20%, and invasive procedures like amniocentesis and CVS show miscarriage risks around 0.1% to 0.2% above background.
report visual · Key figures
How big genetics’ impact is becoming—mortality share and clinical adoption
Genetic-related risk factors account for a meaningful share of adult deaths, while uptake of genetic testing and companion diagnostics continues to grow.
20.8%
In the U.S., 20.8% of adult deaths in 2020 were attributable to genetic, environmental, or behavioral risk factors for a
50%
~50% of Americans have participated in direct-to-consumer genetic testing at least once (survey-based)
19%
In 2023, the FDA approved 19% of drugs in oncology as companion-diagnostic linked (industry-regulatory linkage trend qua
source-verifiedcdc.gov · genomeweb.com · fda.gov2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Genetic Disorders Statistics. Gitnux. https://gitnux.org/genetic-disorders-statistics
MLA
Henrik Dahl. "Genetic Disorders Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/genetic-disorders-statistics.
Chicago
Henrik Dahl. 2026. "Genetic Disorders Statistics." Gitnux. https://gitnux.org/genetic-disorders-statistics.
Sources & references
41 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)